After the FDA said last year it would keep a closer eye on the potential complications of a type of permanent heart plug designed to cut the risk of stroke, Boston Scientific has put forward ...

(Updated) SAN FRANCISCO, California — Preliminary data from the PREVAIL study of the Watchman (AtriTech/Boston Scientific) device for the prevention of stroke and systemic embolism in patients with ...

Abbott's Amplatzer Amulet provided superior left atrial appendage (LAA) closure over the old-guard Watchman (Boston Scientific) device but failed to significantly cut stroke or bleeding rates in ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...

(UPDATED) In patients undergoing left atrial appendage (LAA) occlusion, the Amplatzer Amulet device (Abbott) provides better closure as well as noninferior safety and effectiveness compared with the ...

Please provide your email address to receive an email when new articles are posted on . In a head-to-head trial of the Amplatzer Amulet and Watchman FLX left atrial appendage closure devices, the ...

Sophia Antipolis, France – 30 Aug 2021: The Amplatzer Amulet Left Atrial Appendage Occluder has shown superior left atrial appendage (LAA) closure and noninferior safety and effectiveness for stroke ...

Please provide your email address to receive an email when new articles are posted on . In a head-to-head comparison of two left atrial appendage closure devices for patients with atrial fibrillation, ...

A new device is helping Greeley patients with irregular heartbeats live with a reduced risk of stroke and a greater quality of life. In May, Banner Health’s North Colorado Medical Center became one of ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

More than 8 million people in the U.S. take blood-thinning drugs to prevent life-threatening blood clots, but with that medication comes the potential for serious side effects such as severe bleeding, ...